Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

DTIL earnings analysis

Filed May 5, 2026 · Our reading of the company's report

The latest report

Precision BioSciences reported a significant increase in Q1 2026 revenue to $10.8 million, surpassing expectations of $4.78 million and marking a leap from a mere $29,000 in Q1 2025. Operating expenses decreased,…

Read full summary

Precision BioSciences reported a significant increase in Q1 2026 revenue to $10.8 million, surpassing expectations of $4.78 million and marking a leap from a mere $29,000 in Q1 2025. Operating expenses decreased, resulting in a reduced net loss of $18.4 million, compared to $20.6 million a year prior. The firm maintains a robust cash position of $125.8 million, with sufficient runway to fund operations through 2028, despite ongoing losses.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.75

What stood out

  • Revenue Surges to $10.8M

    Revenue jumped to $10.8 million, up from $29,000 in Q1 2025, benefiting from licensing agreements.

  • Narrowed Net Loss

    Net loss decreased to $18.4 million from $20.6 million year-over-year, reflecting stronger financial management.

  • Improved Cash Position

    Cash and cash equivalents increased to $125.8 million from $99.8 million year-over-year, providing substantial operational runway.

  • R&D Spending Stability

    Research and development costs remained stable at $13.1 million, showing effective cost management amid expansion.

  • Successful Collaboration Update

    The company announced acceptance of a late-breaking poster on PBGENE-HBV at a major medical conference.

  • Regulatory Approval Progress

    PBGENE-DMD received FDA Fast Track designation, potentially expediting development.

What to watch

  • Increased Operating Losses

    Despite lower losses, Q1 2026 reported $18.4 million loss, emphasizing ongoing financial challenges.

  • Heavy Dependence on Third-Party Collaborations

    Future success hinges on third-party performance, which could disrupt timelines if mismanaged.

  • Failure to Meet Nasdaq Requirements

    Past non-compliance with Nasdaq listing standards may impact stock performance and investor sentiment.

Management's outlook

Expecting sufficient cash runway through 2028 to fund research and operations.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.